Cargando…

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study

The global supply of COVID-19 vaccines has been limited, and concerns have arisen about vaccine supply chain disruptions in developing countries. Heterologous prime-boost vaccination, which involves using different vaccines for the first and second doses, has been proposed to enhance the immune resp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tawinprai, Kriangkrai, Jungsomsri, Pawornrath, Pinijnai, Onnicha, Tavonvunchai, Fahsiri, Lievjaroen, Anchisa, Suwannaroj, Paphada, Siripongboonsitti, Taweegrit, Porntharukchareon, Thachanun, Sornsamdang, Gaidganok, Ungtrakul, Teerapat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Coronavirus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294770/ https://www.ncbi.nlm.nih.gov/pubmed/37140889 http://dx.doi.org/10.1080/21645515.2023.2206360

Ejemplares similares

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
por: Cohen, Guy, et al.
Publicado: (2022)

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population
por: Sirisreetreerux, Supamas, et al.
Publicado: (2023)

Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers
por: Dechates, Bothamai, et al.
Publicado: (2023)

Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine
por: Rangsrisaeneepitak, Vimonsri, et al.
Publicado: (2022)

The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study
por: Siripongboonsitti, Taweegrit, et al.
Publicado: (2023)

The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study
por: Porntharukchareon, Thachanun, et al.
Publicado: (2023)

Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial)
por: Muadchimkaew, Marisa, et al.
Publicado: (2022)

Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital
por: Limpawittayakul, Piyarat, et al.
Publicado: (2022)

Transmissibility of SARS-CoV-2 Variants as a Secondary Attack in Thai Households: a Retrospective Study
por: Watanapokasin, Natcha, et al.
Publicado: (2021)

The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study
por: Nontawong, Nuttakant, et al.
Publicado: (2022)

Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV)
por: Siripongboonsitti, Taweegrit, et al.
Publicado: (2023)

Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients
por: Ungtrakul, Teerapat, et al.
Publicado: (2017)

Difference in Immunogenic Responses to COVID-19 Vaccines in Patients With Cancer Receiving Chemotherapy Versus Nonchemotherapy Treatment
por: Tantiyavarong, Walaipan, et al.
Publicado: (2023)

SARS-CoV-2 seroprevalence among cancer patients and household caregivers in a cancer hospital: Cross-sectional survey after the second COVID-19 wave in Thailand
por: Ungtrakul, Teerapat, et al.
Publicado: (2022)

Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand
por: Thonginnetra, Saraiorn, et al.
Publicado: (2022)

367. Role of Conventional Biomarker for Prediction of Chest CT-confirmed COVID-19 Pneumonia
por: Harnphadungkit, Monprach, et al.
Publicado: (2021)

The how’s and what’s of vaccine reactogenicity
por: Hervé, Caroline, et al.
Publicado: (2019)

Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area
por: Ungtrakul, Teerapat, et al.
Publicado: (2016)

Methods for predicting vaccine immunogenicity and reactogenicity
por: Gonzalez-Dias, Patrícia, et al.
Publicado: (2019)

Abnormality Pattern of F-18 FDG PET Whole Body with Functional MRI Brain in Post-Acute COVID-19
por: Kiatkittikul, Peerapon, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity in Q Fever Vaccine Development
por: Fratzke, Alycia P., et al.
Publicado: (2022)

SAT-254 Desmopressin Stimulation Test in a Pregnant Patient with Cushing’s Syndrome
por: Warachit, Wasita, et al.
Publicado: (2020)

Duration of Hepatitis B Vaccine-Induced Protection among Medical Students and Healthcare Workers following Primary Vaccination in Infancy and Rate of Immunity Decline
por: Phattraprayoon, Nanthida, et al.
Publicado: (2022)

Desmopressin Stimulation Test in a Pregnant Patient with Cushing's Disease
por: Parksook, Wasita Warachit, et al.
Publicado: (2021)

Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies
por: Thookhamme, Chayapa, et al.
Publicado: (2023)

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
por: Al Bahrani, Salma, et al.
Publicado: (2021)

COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
por: Briggs, Farren Basil Shaw, et al.
Publicado: (2021)

Reactogenicity to COVID-19 vaccination in the United States of America
por: Sanyaolu, Adekunle, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

Editorial: Non-reactogenic vaccines against Q-fever
por: Gregory, Anthony E., et al.
Publicado: (2023)

Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV
por: Motta, Edwiges, et al.
Publicado: (2023)

Concomitant administration of COVD-19 vaccines with 'flu vaccines: acceptable reactogenicity profiles
Publicado: (2021)

SAT-324 An Unusual Association between Pheochromocytoma and Hyperparathyroidism in a Patient with Neurofibromatosis Type 1: A Possible Co-Occurrence of Two Hereditary Endocrine Tumor Syndromes
por: Kiatpanabhikul, Phatharaporn, et al.
Publicado: (2019)

Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report
por: Porntharukchareon, Thachanun, et al.
Publicado: (2020)

Standardized guinea pig model for Q fever vaccine reactogenicity
por: Baeten, Laurie A., et al.
Publicado: (2018)

Can reactogenicity predict immunogenicity after COVID-19 vaccination?
por: Hwang, Young Hoon, et al.
Publicado: (2021)

Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
por: Mahallawi, Waleed H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_751vjiut48bukt8jmcgep099e0